pre-IPO PHARMA

COMPANY OVERVIEW

Slayback Pharma LLC is a specialty pharmaceutical company focused on developing, manufacturing and sourcing of complex generic pharmaceutical products, with a specific emphasis on complex injectables and other non-solid oral products. Slayback has created a unique portfolio of complex generics by smart product selection and execution and connecting various dots through a network of contract R&D laboratories and manufacturing organizations, comprising smart and rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies.


LOCATION

  • Princeton, NJ, USA

  • THERAPEUTIC AREAS

  • Women's Health

  • WEBSITE

    https://www.slayback-pharma.com


    CAREER WEBSITE

    https://www.slayback-pharma.com/careers/


    SOCIAL MEDIA


    INVESTORS

    kkr


    PRESS RELEASES


    Apr 26, 2023

    Endo Announces Agreement with Slayback Pharma to Distribute Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Product in the U.S.


    Jul 29, 2022

    Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify in the U.S.


    Feb 4, 2021

    Slayback Pharma announces launch of Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg, generic equivalent of Taytulla


    Dec 18, 2020

    Slayback Pharma announces FDA approval of Merzee, generic equivalent of Taytulla with a Competitive Generic Therapy (CGT) Designation


    Dec 7, 2020

    Slayback Pharma Appoints Dr Sumitra Pillai as Head of RandD


    For More Press Releases


    Google Analytics Alternative